Johnson & Johnson

NYSE: JNJ
$133.29
+$10.13 (+8.2%)
Real time price as of March 30, 2020 3:50 pm EDT
Wednesday's top analyst upgrades, downgrades and initiations include Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, Johnson & Johnson, Replimune, Schlumberger and Transocean.
Jon C. Ogg
Despite the never-ending election cycle, there actually is a clear path for the Dow to hit 30,000 as soon as early 2020, if only a few things come to fruition. There does not even have to be a big...
Jon C. Ogg
With markets at all-time highs, it's important to consider the winners and losers. In this case, many stocks in the Dow are still holding the index back from even stronger gains.
Jon C. Ogg
Goldman Sachs may have the best strategy for investors for 2020. Here are five stocks that look like great ideas now for investors looking to mold such a plan.
Lee Jackson
Johnson & Johnson has found itself involved in more controversy than the company would prefer to see. But it seems that not even bad news lasts forever.
Jon C. Ogg
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Jon C. Ogg
Wednesday's top analyst upgrades, downgrades and initiations included Adobe, Alibaba, Amazon.com, AT&T, Comcast, Delphi Technologies, DocuSign, Johnson & Johnson, JPMorgan, T-Mobile, Verizon...
Jon C. Ogg
Johnson & Johnson reported better than expected quarterly results before the markets opened on Tuesday.
Chris Lange
Johnson & Johnson is scheduled to report its most recent quarterly results before the markets open on Tuesday, and analysts' expectations are mild overall.
Chris Lange
Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
Chris Lange
Friday's top analyst upgrades, downgrades and initiations included Apple, Canopy Growth, CrowdStrike, Delta Air Lines, Johnson & Johnson, Rio Tinto, Roku, Square, Tilray and Twilio.
Jon C. Ogg
Johnson & Johnson shares dropped on Wednesday following the announcement that a jury has awarded $8 billion in damages to a man accusing the drugmaker of failing to warn about the side effects of...
Chris Lange
One analyst issued a fairly bullish report in response to Johnson & Johnson's announcement of a $10 million settlement with two Ohio counties ahead of an upcoming opioid trial.
Chris Lange
Five drugmakers are considering a proposal that would have them contribute to a trust established as part of the bankruptcy settlement by Purdue Pharmaceuticals and be released from liability in the...
Paul Ausick
The last thing investors want is a value trap loser that stays stagnant, but all these top companies have solid long-term prospects.
Lee Jackson